| 主权项 |
1. A method of treating a coarctation of the aorta in a human patient comprising:
identifying a narrowed segment in the aorta of a human child who is born with a coarctation of the aorta, wherein the aorta narrows in an area where the ductus arteriosus inserts in the aorta; deploying a bioabsorbable polymer scaffold at the narrowed segment; wherein the deployed bioabsorbable polymer scaffold provides support at the segment at an increased diameter; wherein the deployed bioabsorbable polymer scaffold eventually completely absorbs away; wherein the bioabsorbable polymer scaffold comprises poly(L-lactide) (PLLA), wherein the PLLA has an initial molecular weight (Mn(0)) of at least 60 kDa, 60 to 66 kDa, 66 to 80 kDa, 80 to 120 kDa, or greater than 120 kDa and an initial L-lactide monomer content within the range less than 0.02 wt %, 0.02 wt % to 0.2 wt %, or 0.02 wt % to 1 wt %; or the bioabsorbable polymer scaffold comprises, poly(L-lactide) (PLLA) or poly(L-lactide-co-glycolide) (PLLGA), in combination with a lower modulus polymer selected from the group consisting of polycaprolactone (PCL), poly(trimethylene carbonate) (PTMC), polydioxanone (PDO), poly(4-hydroxy butyrate) (PHB), poly(butylene succinate) (PBS), poly(L-lactide)-co-polycaprolactone (PLLA-co-PCL), poly(L-lactide)-b-polycaprolactone (PLLA-b-PCL), and blends and copolymers thereof; wherein the deployed bioabsorbable polymer scaffold maintains a radial strength of at least 200 mm Hg for at least 6 months. |
